Thymosin alpha1. SciClone Pharmaceuticals.
Level 5 - mechanism / opinion, no new human data
Narrative review and commercial drug development profile with no primary clinical data
What was done
This is a narrative drug development profile reviewing the pharmacology, proposed mechanism of action, clinical trial status, global regulatory approvals, and patent portfolio for thymosin alpha-1 (Talpha1; Zadaxin, SciClone Pharmaceuticals), a synthetic 28-amino acid peptide investigated for hepatitis B, hepatitis C, and various cancers.
What was found
The abstract provides no quantitative clinical outcome data or effect sizes. It reports that thymosin alpha-1 enhances immune response, potentiates cytokine action, and reduces hematological toxicity from certain cytotoxic chemotherapy regimens. It summarizes marketing approvals across multiple countries for HBV and HCV, Phase III US trial activity, and international patent filings through 2001.
Why it matters
The profile documents the early-2000s regulatory, patent, and clinical landscape of thymosin alpha-1 as an immunomodulator and vaccine/chemotherapy adjuvant.
Limits
This is a narrative drug profile without primary empirical data, control groups, or statistical findings presented in the abstract. Efficacy and safety cannot be evaluated from this record.
Cited by
- supports In several countries outside the US, thymosin alpha-1 is approved as an adjuvant treatment for hepatitis B, hepatitis C, and specific cancers.
- contradicts Thymosin alpha-1 was previously FDA-approved under the brand name Zadaxin for conditions involving thymic abnormalities like DiGeorge syndrome.